Clementis de-risks breakthrough science and carries it from preclinical concept to market-ready launch — across nanotechnology, precision medicine, functional biomaterials and evidence-based nutraceuticals.
Commercial delivery across 4 continents / ANVISA-registered products / Fulbright-scholar founder
Between a promising result and a product that regulators approve, investors fund, and manufacturers can scale, sit a series of unglamorous gaps. Clementis finds them early — and closes them methodically.
Seven fields where scientific depth changes the commercial outcome — and where a generalist consultancy cannot follow.
Green-synthesis platforms, nanomaterial characterization, and safe-by-design commercialization.
Mechanistic positioning and evidence strategy for targeted, patient-specific therapeutics.
Bioactive barrier and surface technologies engineered for performance and safety.
Materials designed for scalability, circularity and regulatory durability.
Claim substantiation, formulation logic and multi-market compliance for functional products.
Cancer-focused nanomaterials and radiolabeled imaging from concept toward the clinic.
Cleaner routes and phytochemical platforms that hold up commercially and environmentally.
Bridging nanoscience and business strategy across adjacent deep-tech domains.
Every engagement moves through four stages. Each one ends in an explicit decision — so capital and time are only committed once the evidence earns it.
Map the science, IP landscape, and market. Separate what is proven from what is assumed.
Audit the programme against readiness criteria, build the risk register, and close critical gaps.
Define the target product profile, regulatory route, and mechanistic story that will hold up.
Coordinate partners, CROs, and filings toward regulatory-aligned, scalable market entry.
Comprehensive translational R&D strategy — engaged as a full programme or a single focused workstream.
Preclinical roadmap design, Structure–Activity Relationship (SAR) optimization, and mechanistic positioning that stands up to scientific and investor scrutiny.
Market research analysis and target product profile planning — so the science is aimed at a defensible, differentiated commercial position from the start.
Translational program audits (proven vs. missing data), risk registers, and explicit go/no-go decision gates that protect capital and credibility.
Clinical readiness frameworks and evidence planning across FDA, EMA, ANVISA, PMDA, CDSCO and SAHPRA — mapped to your lead markets.
IP landscape strategy, freedom-to-operate, partner identification, and coordination with universities and CROs to resource the critical path.
A track record of taking green-nanotechnology and functional-product programmes through regulation and into commercial reality.
Green-nanotechnology silver-nanoparticle (AgNP) respiratory filter with a Youshield Ag® electrostatic membrane, developed in collaboration with IPEN and registered with ANVISA.
R&D lead for a bioidentical ketone platform rooted in “battlefield science,” translating military-grade nutrition into a civilian metabolic-health and cognition portfolio.
Proprietary green-nanotechnology platforms commercialized into natural, bio-compatible products — from gold face cream to silver anti-dandruff shampoo and antioxidant serum.
Strategy for a Nano-Ayurveda platform integrating African botanicals (Rooibos, Marula, Moringa) with green nanotechnology, targeting a multi-billion-dollar beauty and nutraceutical market.
Answer six questions and get an instant readiness score across evidence, IP, regulatory, market, manufacturing and partnerships — with the specific gaps to close first.
A scientist and strategist bridging nanoscience and business, with cross-continental experience spanning South Africa, the United States, Brazil, India and Japan.
Ph.D. in Chemistry (Fulbright Scholar) and MBA in Life-Sciences Innovation from the University of Missouri; M.Sc. in Nanoscience and B.S. in Biotechnology from the University of Johannesburg. Former postdoctoral fellow in Radiology and affiliate of the Institute of Green Nanotechnology.
Green nanotechnology & phytochemicals, cancer-focused nanomaterials, radiolabeled nanoparticle imaging, bioactive barrier technology.
ANVISA registration secured; fluent across FDA, EMA, PMDA, CDSCO and SAHPRA pathways; U.S. patents pending.
Featured on KOMU 8 News and TEDxCoMo; affiliate of the Institute of Green Nanotechnology, University of Missouri.
Start with a complimentary discovery call, or run the free readiness assessment first.